Preoperative Chemoradiotherapy With Capecitabine With or Without Temozolomide in Patients With Locally Advanced Rectal Cancer: A Prospective, Randomised Phase II Study Stratified by O6-Methylguanine DNA Methyltransferase Status: KCSG-CO17-02-Reference-Cited by-同舟云学术

Preoperative Chemoradiotherapy With Capecitabine With or Without Temozolomide in Patients With Locally Advanced Rectal Cancer: A Prospective, Randomised Phase II Study Stratified by O6-Methylguanine DNA Methyltransferase Status: KCSG-CO17-02

Published:2023-02 Issue:2 Volume:35 Page:e143-e152
ISSN:0936-6555
Container-title:Clinical Oncology
language:en
Short-container-title:Clinical Oncology

Author:

Oh C.R.,Kim J.E.,Lee J.S.,Kim S.Y.,Kim T.W.,Choi J.,Kim J.,Park I.J.,Lim S.-B.,Park J.-h.,Kim J.H.,Choi M.K.,Cha Y.,Baek J.Y.,Beom S.-H.,Hong Y.S.

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology

Reference38 articles.

1. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data;Maas;Lancet Oncol,2010

2. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer;Park;J Clin Oncol,2012

3. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial;Bahadoer;Lancet Oncol,2021

4. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial;Conroy;Lancet Oncol,2021

5. Randomized phase II trial chemotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12;Fokas;J Clin Oncol,2019

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Surgical Management and Long-Term Evaluation of Pancreatic Neuroendocrine Tumors;Surgical Clinics of North America;2024-08